Physician profile
Victoria Walker
NPI 1942762802
$2,101.44
in general payments reported to CMS, 2019-2025
21 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.54 · 2020: $48.62 · 2021: $670 · 2022: $475 · 2023: $49.85 · 2024: $322 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $550.17 | 2021-2022 | |
| Cvrx, INC. | $213.45 | 2024 | Barostim Neo System |
| Alexion Pharmaceuticals, INC. | $143.90 | 2021 | |
| Genzyme Corporation | $143.65 | 2025 | |
| United Therapeutics Corporation | $139.87 | 2025 | Tyvaso, Orenitram, Remodulin |
| Astrazeneca Pharmaceuticals Lp | $124.96 | 2021 | |
| Merck Sharp & Dohme LLC | $123.34 | 2024-2025 | Winrevair, Zerbaxa |
| E.R. Squibb & Sons, L.L.C. | $116.46 | 2021-2022 | |
| Insmed, INC. | $85.08 | 2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $63.19 | 2022-2024 | Opsumit, Uptravi |
| Melinta Therapeutics, LLC | $63.16 | 2021-2024 | Rezzayo, Kimyrsa |
| Grifols USA, LLC | $54.12 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Shionogi INC | $52.21 | 2022-2024 | Fetroja |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.48 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.45 | 2022 | |
| Aroa Biosurgery Incorporated | $26.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2023 | Jardiance |
| Genentech USA, INC. | $18.94 | 2021 | |
| Amgen INC. | $17.45 | 2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $15.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.